Affymax, Inc. (AFFY)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2013 | -14.29 Million USD | 59.47% |
| 2012 | -89.93 Million USD | -55.72% |
| 2011 | -59.04 Million USD | -316.67% |
| 2010 | -11.72 Million USD | 81.32% |
| 2009 | -75.72 Million USD | 11.45% |
| 2008 | -84.32 Million USD | -76.45% |
| 2007 | -48.52 Million USD | 8.3% |
| 2006 | -53 Million USD | -58.91% |
| 2005 | -33.28 Million USD | -54.74% |
| 2004 | -21.25 Million USD | -9672.89% |
| 2003 | 225 Thousand USD | 101.03% |
| 2002 | -22.26 Million USD | -1064.4% |
| 2001 | 2.27 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2014 Q1 | -1.49 Million USD | -115.44% |
| 2014 Q2 | -1.02 Million USD | 31.41% |
| 2013 Q2 | -2.04 Million USD | 83.57% |
| 2013 Q3 | -1.38 Million USD | 32.09% |
| 2013 Q4 | -693 Thousand USD | 50.07% |
| 2013 Q1 | -12.43 Million USD | 81.75% |
| 2013 FY | - USD | 59.47% |
| 2012 FY | - USD | -55.72% |
| 2012 Q4 | -68.16 Million USD | -184.42% |
| 2012 Q3 | -23.96 Million USD | 22.35% |
| 2012 Q2 | -30.86 Million USD | -197.88% |
| 2012 Q1 | 31.53 Million USD | 209.12% |
| 2011 Q4 | -28.89 Million USD | -213.26% |
| 2011 FY | - USD | -316.67% |
| 2011 Q2 | -11.9 Million USD | -31.91% |
| 2011 Q3 | -9.22 Million USD | 22.52% |
| 2011 Q1 | -9.02 Million USD | 19.01% |
| 2010 Q2 | 17.9 Million USD | 348.27% |
| 2010 FY | - USD | 81.32% |
| 2010 Q4 | -11.14 Million USD | 3.16% |
| 2010 Q3 | -11.5 Million USD | -164.28% |
| 2010 Q1 | -7.21 Million USD | 51.89% |
| 2009 Q2 | -21.73 Million USD | -2.74% |
| 2009 FY | - USD | 11.45% |
| 2009 Q4 | -14.99 Million USD | 16.76% |
| 2009 Q3 | -18 Million USD | 17.16% |
| 2009 Q1 | -21.15 Million USD | 20.42% |
| 2008 Q3 | -25.59 Million USD | -35.02% |
| 2008 Q2 | -18.95 Million USD | -30.14% |
| 2008 Q4 | -26.58 Million USD | -3.88% |
| 2008 FY | - USD | -76.45% |
| 2008 Q1 | -14.56 Million USD | -4.36% |
| 2007 Q4 | -13.95 Million USD | -0.61% |
| 2007 Q2 | -11.02 Million USD | -14.06% |
| 2007 Q1 | -9.66 Million USD | -63.54% |
| 2007 FY | - USD | 8.3% |
| 2007 Q3 | -13.87 Million USD | -25.82% |
| 2006 Q4 | -5.91 Million USD | -1.98% |
| 2006 Q3 | -5.79 Million USD | 81.05% |
| 2006 FY | - USD | -58.91% |
| 2006 Q2 | -30.58 Million USD | -186.44% |
| 2006 Q1 | -10.67 Million USD | 68.67% |
| 2005 Q3 | 22 Thousand USD | 0.0% |
| 2005 Q1 | 22 Thousand USD | 100.1% |
| 2005 Q4 | -34.07 Million USD | -154990.91% |
| 2005 FY | - USD | -54.74% |
| 2005 Q2 | 22 Thousand USD | 0.0% |
| 2004 Q2 | 38 Thousand USD | 0.0% |
| 2004 Q1 | 38 Thousand USD | 0.0% |
| 2004 FY | - USD | -9672.89% |
| 2004 Q4 | -22.23 Million USD | -58602.63% |
| 2004 Q3 | 38 Thousand USD | 0.0% |
| 2003 FY | - USD | 101.03% |
| 2002 FY | - USD | -1064.4% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 79.876% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -141.107% |
| SQZ Biotechnologies Company | -64.14 Million USD | 77.713% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 17.703% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 115.201% |
| Mesoblast Limited | -62.38 Million USD | 77.088% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -830.634% |
| Genus plc | 73.7 Million USD | 119.396% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -116.214% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -303.017% |
| Marizyme, Inc. | -34.28 Million USD | 58.301% |
| ContraFect Corporation | -64.99 Million USD | 78.007% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -62.962% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -215.828% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -919.754% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -440.566% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -515.151% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2659.407% |
| Accustem Sciences Inc. | -3.74 Million USD | -281.564% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 70.359% |
| EV Biologics, Inc. | -1.26 Million USD | -1028.138% |
| Q BioMed Inc. | -617.62 Thousand USD | -2214.5% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 500.196% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2160.415% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -525.742% |
| Biomind Labs Inc. | -1.03 Million USD | -1281.761% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 244.73% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -99.615% |
| Skye Bioscience, Inc. | -13.54 Million USD | -5.517% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -861.065% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -57079.996% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -268.018% |
| IMV Inc. | -35.52 Million USD | 59.759% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 9.923% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -471.352% |
| GB Sciences, Inc. | -1.41 Million USD | -906.772% |
| Alpha Cognition Inc. | -9.7 Million USD | -47.286% |
| HST Global, Inc. | -5303.00 USD | -269464.379% |
| CSL Limited | 4.78 Billion USD | 100.298% |
| Halberd Corporation | -74.27 Thousand USD | -19145.007% |
| Enzolytics Inc. | -2.12 Million USD | -573.648% |
| Resverlogix Corp. | -11.74 Million USD | -21.742% |
| SYBLEU INC | -141.57 Thousand USD | -9997.406% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -366.697% |
| argenx SE | -216.02 Million USD | 93.383% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 74.168% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1274.61% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -853.695% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3873.321% |
| AVAX Technologies, Inc. | -6.11 Million USD | -133.86% |
| Zenith Capital Corp. | -8.6 Million USD | -66.105% |
| Genscript Biotech Corporation | -248.71 Million USD | 94.253% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -81956.133% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -484.313% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -8021.034% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 63.935% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -394.239% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1266.227% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 212696.654% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -716.858% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -644.178% |
| BioStem Technologies, Inc. | -7.55 Million USD | -89.246% |
| ONE Bio Corp. | 13.61 Million USD | 205.01% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -7793.952% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -594.944% |
| Agentix Corp. | -1.37 Million USD | -942.095% |
| LadRx Corporation | 412.28 Thousand USD | 3567.278% |
| Cell Source, Inc. | -4.27 Million USD | -234.58% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3792.751% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1075.132% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1425.697% |
| NovAccess Global Inc. | -1.03 Million USD | -1281.43% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 261.456% |
| Itoco Inc. | -1.86 Million USD | -664.85% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3665.607% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1180.914% |
| Kadimastem Ltd | -2.62 Million USD | -444.7% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -5877.42% |
| CytoDyn Inc. | -18.02 Million USD | 20.711% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -17988.295% |
| Mobile Lads Corp. | -2.24 Million USD | -537.84% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -116794.26% |
| Qrons Inc. | -40.08 Thousand USD | -35565.275% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2843.308% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2810.297% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1403.154% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1246.032% |
| International Stem Cell Corporation | 202 Thousand USD | 7176.732% |
| Bioxytran, Inc. | -3.82 Million USD | -274.2% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -27056.153% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -480.642% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 60.147% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -31666.664% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -422.096% |
| Neutra Corp. | -181.24 Thousand USD | -7787.027% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 29.089% |
| PureTech Health plc | -11.62 Million USD | -22.947% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 29.084% |
| IXICO plc | -707 Thousand USD | -1921.923% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -86.012% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 70.432% |
| CSL Limited | 4.73 Billion USD | 100.302% |
| Cellectis S.A. | -92.63 Million USD | 84.569% |